COMMUNIQUÉS West-GlobeNewswire

Microbix Reports Record Results for Q1 Fiscal 2024
14/02/2024
Record Revenues of $8.4 million and Record Net Income of $2.5 million MISSISSAUGA, Ontario, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, [...]
Shineco Announces 1-for-10 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
14/02/2024
BEIJING, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that the Company’s Board of [...]
Healthcare Triangle Unveils New SaaS Solutions to Drive Digital Transformation and AI Integration in Healthcare
14/02/2024
Company positioned at forefront of $208 billion global AI in healthcare market by 2030 PLEASANTON, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the [...]
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
14/02/2024
TScan’s abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of initial data from a large prospective clinical trial assessing the relationship between [...]
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
14/02/2024
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 [...]
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
14/02/2024
COAST trial is evaluating the superiority of sozinibercept combined with EYLEA ® (aflibercept) over EYLEA alone in wet AMD Enrollment of second pivotal trial (ShORe) to complete in calendar Q2 2024 COAST and ShORe top- [...]
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
14/02/2024
Pro-forma cash, cash equivalents and marketable securities expected to fund the Company into 2027 and through clinical readouts from ongoing SUMMIT, PEAK and APEX registration-directed trials Cogent to host investor [...]
Blue Point Brewing Announces Its 4th Annual Shakedown on Main Street Festival Featuring Headliners Shaggy, Bryce Vine, and B.o.B
14/02/2024
Blue Point Celebrates 4/20 Bigger than Ever with 2 Stages of Live Music, Art Installations, Skateboarding Demos, and more PATCHOGUE, New York, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Blue Point Brewing Company, Long Island’s [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
14/02/2024
Bagsværd, Denmark, 14 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
14/02/2024
BALA CYNWYD, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
14/02/2024
VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]
Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
14/02/2024
STAFFORD, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to [...]
Grifols announces positive topline phase 3 fibrinogen clinical trial results
14/02/2024
In the AdFIrst study, Biotest's fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired fibrinogen deficiency (AFD) as equivalent to standard of care, while [...]
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer
14/02/2024
NM49 is a multi-specific antibody identified through Numab’s proprietary discovery and engineering technology platform designed to activate tumor associated macrophage phagocytosis Numab to receive upfront payment and [...]
Iktos opens a subsidiary in Japan and entrusts its management to Hideyoshi Fuji
14/02/2024
Paris (France) and Tokyo (Japan), February 14, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the opening of Iktos K.K., its new subsidiary in Japan. Hideyoshi Fuji has [...]
TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research
14/02/2024
Project Grant for Development of Company’s Lead Clinical Program HELSINKI, Finland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies [...]
Mendus AB Year-end Report for 2023
14/02/2024
Press Release Stockholm, Sweden, February 14, 2024 Positive ADVANCE II data at ASH caps strong 2023 The fourth quarter of 2023 closes a crucial year for Mendus and delivered additional milestones to further strengthen [...]
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology
14/02/2024
Results from 112 patients with DMD who completed the study confirm maintenance of efficacy and benefits in safety and tolerability of treatment with vamorolone over 48 weeks AGAMREE® has shown safety benefits in [...]
PCI Biotech second half 2023 interim results
14/02/2024
Oslo (Norway), 14 February 2024 – PCI Biotech (OSE: PCIB), today announces its interim second half 2023 results. Please find enclosed the interim report and presentation. Highlights review Operations The use of fima NAc [...]

Pages